Brief: Cereno Scientific Submits Trial Protocol To U.S. FDA
10/11/2025 06:49
Nov 10 (Reuters) - Cereno Scientific AB CRNOSb.ST: SUBMITS PHASE IIB TRIAL PROTOCOL FOR CS1 IN PULMONARY ARTERIAL HYPERTENSION (PAH) TO U.S. FDA ANTICIPATES FDA CLEARANCE FOR TRIAL IN H1 2026 PHASE IIB TRIAL PLANNED TO BEGIN DURING H1 2026 Source text: ID:nWkr1D1JHL Further company coverage: CRNOSb.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Cereno Scientific AB
See all newsBrief: Cereno Scientific Expects Up To 15 Activated Sites By 2026 In Epimode Trial
Brief: Cereno Scientific Reports Positive Results From Study
Brief: Cereno Scientific Q2 Net Sales Sek 0
Sweden's Cereno Scientific Q2 net loss widens, hurt by clinical development costs
Brief: Cereno Scientific Q2 Loss After Financial Items SEK 30.5 Mln